Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that more than half of the world’s top 25 pharmaceutical companies have adopted Genedata Screener as their plate-based screening analysis platform. Also used by biotechnology companies, contract research organizations, and academic research institutions, Genedata Screener captures, analyzes, and manages all types of screening data on one platform. The system, which reduces data processing times by upwards to 80%, integrates with any plate-based instrument to support High, Medium and Low Throughput Screening, High Content Screening (HCS), Ion Channel Screening, Label-free (including thermal shift), and other assay technologies. Genedata Screener will be demonstrated at the 2nd Annual SLAS Conference at the Gaylord Palms Convention Center (Booth #511) with a featured tutorial scheduled for January 15.
One Platform for All Plate-based Screening
The cost savings, productivity gains, and time efficiencies of a single-platform screening analysis system with built-in business logic for standardized and automated workflows are driving the accelerated adoption of Genedata Screener. Addressing the complete screening workflow, Genedata Screener scales from the smallest datasets with single read-outs per well to 1,000s of plates in 1536-well format with full kinetics resolution. Its intuitive data analysis environment enables very fast experiment set-up, data import and processing with set-up times reduced by more than 50% compared to other systems. Genedata Screener uniquely supports the complete range of:
Industry Adoption – Co-Development Drives Innvovation
The system’s data analysis capabilities are further advanced through co-development projects with leading pharmaceutical companies. Currently, the Genedata team is working with customers to have Genedata Screener support native processing for calculation of compound combination effects – such as synergy or antagonistic effects. Exploring compound combination effects is a rapidly expanding field in pharmaceutical and biotechnology research. Genedata Screener provides a standardized platform on which researchers can systematically, reliably and efficiently visualize and explore the scientific principles of compound combinations is critical to furthering innovation in drug and treatment discovery.
“Over the past two years, we have seen Genedata Screener’s adoption more than double, making it the de-facto screening analysis standard at leading pharmaceutical companies,” said Dr. Othmar Pfannes, CEO of Genedata. “The increased use of Genedata Screener is also due in part to our commitment to industry collaborations that drive innovative research. For example, our collaborations will develop the industry’s first commercial platform to fully support quantification of drug combination effect as part of a complete interactive and multi-dimensional screening workflow.”
Editorial Note: SLAS Tutorial – “One Platform for All Plate-based Screening” – January 15, 2013; 2:00pm – 2:45pm; Room Destin 1-2. Demonstration will show how raw data and results are managed on one platform to drive continual comparability, efficient data analysis, and improved results.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.